Cargando…
Mitotic and Proliferative Indices in WHO Grade III Meningioma
SIMPLE SUMMARY: Malignant meningiomas are rare primary intracranial tumors associated with considerable morbidity and mortality. The diagnosis is based on the number of mitotic figures (mitotic index, MI). Consequently, the quantification of mitotic figures is prone to inter- and intraobserver varia...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697885/ https://www.ncbi.nlm.nih.gov/pubmed/33198268 http://dx.doi.org/10.3390/cancers12113351 |
_version_ | 1783615701435547648 |
---|---|
author | Daniela Maier, Andrea Brøchner, Christian Beltoft Bartek Jr., Jiri Eriksson, Frank Ugleholdt, Heidi Broholm, Helle Mathiesen, Tiit |
author_facet | Daniela Maier, Andrea Brøchner, Christian Beltoft Bartek Jr., Jiri Eriksson, Frank Ugleholdt, Heidi Broholm, Helle Mathiesen, Tiit |
author_sort | Daniela Maier, Andrea |
collection | PubMed |
description | SIMPLE SUMMARY: Malignant meningiomas are rare primary intracranial tumors associated with considerable morbidity and mortality. The diagnosis is based on the number of mitotic figures (mitotic index, MI). Consequently, the quantification of mitotic figures is prone to inter- and intraobserver variability. The mitotic marker, phosphohistone-H3 (PHH3), has been shown to be a more robust mitotic marker. Despite the prognostic value of MI across all meningioma grades, little is known of the prognostic value of the MI within malignant meningioma. Therefore, this study investigates the MI in a series of malignant meningiomas to analyze the association to progression-free survival and mitotic and proliferative indices. Furthermore, we investigated the precision (repeatability) of mitotic counts and the agreement between MI and PHH3 MI. ABSTRACT: Meningiomas with inherently high mitotic indices and poor prognosis, such as WHO grade III meningiomas, have not been investigated separately to establish interchangeability between conventional mitotic index counted on H&E stained slides (MI) and mitotic index counted on phosphohistone-H3 stained slides (PHH3 MI). This study investigates the agreement of MI and PHH3 MI and to analyze the association of progression-free survival (PFS) and MI, PHH3 MI, and the proliferative index (PI, Ki-67) in WHO grade III meningioma. Tumor specimens from 24 consecutive patients were analyzed for expression of Ki-67, PHH3 MI, and MI. Quantification was performed independently by two observers who made replicate counts in hot spots and overall tumor staining. Repeatability in replicate counts from MI and PHH3 MI was low in both observers. Consequently, we could not report the agreement. MI, PHH3 MI and hot spot counts of Ki-67 were associated with PFS (MI hot spot HR = 1.61, 95% CI 1.12–2.31, p = 0.010; PHH3 MI hot spot HR = 1.59, 95% CI 1.15–2.21, p = 0.006; Ki-67 hot spot HR = 1.06, 95% CI 1.02–1.11. p = 0.004). We found markedly low repeatability of manually counted MI and PHH3 MI in WHO grade III meningioma, and we could not conclude that the two methods agreed. Subsequently, quantification with better repeatability should be sought. All three biomarkers were associated with PFS. |
format | Online Article Text |
id | pubmed-7697885 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76978852020-11-29 Mitotic and Proliferative Indices in WHO Grade III Meningioma Daniela Maier, Andrea Brøchner, Christian Beltoft Bartek Jr., Jiri Eriksson, Frank Ugleholdt, Heidi Broholm, Helle Mathiesen, Tiit Cancers (Basel) Article SIMPLE SUMMARY: Malignant meningiomas are rare primary intracranial tumors associated with considerable morbidity and mortality. The diagnosis is based on the number of mitotic figures (mitotic index, MI). Consequently, the quantification of mitotic figures is prone to inter- and intraobserver variability. The mitotic marker, phosphohistone-H3 (PHH3), has been shown to be a more robust mitotic marker. Despite the prognostic value of MI across all meningioma grades, little is known of the prognostic value of the MI within malignant meningioma. Therefore, this study investigates the MI in a series of malignant meningiomas to analyze the association to progression-free survival and mitotic and proliferative indices. Furthermore, we investigated the precision (repeatability) of mitotic counts and the agreement between MI and PHH3 MI. ABSTRACT: Meningiomas with inherently high mitotic indices and poor prognosis, such as WHO grade III meningiomas, have not been investigated separately to establish interchangeability between conventional mitotic index counted on H&E stained slides (MI) and mitotic index counted on phosphohistone-H3 stained slides (PHH3 MI). This study investigates the agreement of MI and PHH3 MI and to analyze the association of progression-free survival (PFS) and MI, PHH3 MI, and the proliferative index (PI, Ki-67) in WHO grade III meningioma. Tumor specimens from 24 consecutive patients were analyzed for expression of Ki-67, PHH3 MI, and MI. Quantification was performed independently by two observers who made replicate counts in hot spots and overall tumor staining. Repeatability in replicate counts from MI and PHH3 MI was low in both observers. Consequently, we could not report the agreement. MI, PHH3 MI and hot spot counts of Ki-67 were associated with PFS (MI hot spot HR = 1.61, 95% CI 1.12–2.31, p = 0.010; PHH3 MI hot spot HR = 1.59, 95% CI 1.15–2.21, p = 0.006; Ki-67 hot spot HR = 1.06, 95% CI 1.02–1.11. p = 0.004). We found markedly low repeatability of manually counted MI and PHH3 MI in WHO grade III meningioma, and we could not conclude that the two methods agreed. Subsequently, quantification with better repeatability should be sought. All three biomarkers were associated with PFS. MDPI 2020-11-12 /pmc/articles/PMC7697885/ /pubmed/33198268 http://dx.doi.org/10.3390/cancers12113351 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Daniela Maier, Andrea Brøchner, Christian Beltoft Bartek Jr., Jiri Eriksson, Frank Ugleholdt, Heidi Broholm, Helle Mathiesen, Tiit Mitotic and Proliferative Indices in WHO Grade III Meningioma |
title | Mitotic and Proliferative Indices in WHO Grade III Meningioma |
title_full | Mitotic and Proliferative Indices in WHO Grade III Meningioma |
title_fullStr | Mitotic and Proliferative Indices in WHO Grade III Meningioma |
title_full_unstemmed | Mitotic and Proliferative Indices in WHO Grade III Meningioma |
title_short | Mitotic and Proliferative Indices in WHO Grade III Meningioma |
title_sort | mitotic and proliferative indices in who grade iii meningioma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697885/ https://www.ncbi.nlm.nih.gov/pubmed/33198268 http://dx.doi.org/10.3390/cancers12113351 |
work_keys_str_mv | AT danielamaierandrea mitoticandproliferativeindicesinwhogradeiiimeningioma AT brøchnerchristianbeltoft mitoticandproliferativeindicesinwhogradeiiimeningioma AT bartekjrjiri mitoticandproliferativeindicesinwhogradeiiimeningioma AT erikssonfrank mitoticandproliferativeindicesinwhogradeiiimeningioma AT ugleholdtheidi mitoticandproliferativeindicesinwhogradeiiimeningioma AT broholmhelle mitoticandproliferativeindicesinwhogradeiiimeningioma AT mathiesentiit mitoticandproliferativeindicesinwhogradeiiimeningioma |